TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00567489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physioneal
Description: Physioneal 40 or Physioneal 35

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal
Description: 7.5% Icodextrin
Study: NCT04252469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral care
Description: oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
Study: NCT01085344

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)
Description: escalating dose prophylaxis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)
Description: escalating dose
Study: NCT01576978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hatha yoga
Description: The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hatha yoga
Description: The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
Study: NCT01550211

Intervention type: DEVICE
Intervention: Magnetoencephalograph (MEG)
Description: Conducting a brain scan during a series of perceptual and linguistic tasks

Intervention type: DEVICE
Intervention: Magnetoencephalograph (MEG)
Description: Conducting a brain scan during a series of perceptual and linguistic tasks

Intervention type: DEVICE
Intervention: Magnetoencephalograph (MEG)
Description: Conducting a brain scan during a series of perceptual and linguistic tasks

Intervention type: DEVICE
Intervention: Magnetoencephalograph (MEG)
Description: Conducting a brain scan during a series of perceptual and linguistic tasks
Study: NCT01637038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study: NCT01625377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
Study: NCT00721643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: angel's plant (Angelica keiskei)
Description: Healthy control, one time dose of 5g dry power of Angelica keiskei

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angel's plant (Angelica keiskei)
Description: Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
Study: NCT03037879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPT
Description: Participants in the SPT group will receive 10 training sessions over 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPT Control
Description: Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mSMT
Description: Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mSMT Control
Description: Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
Study: NCT02388074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPath®
Description: CyPath® diagnostic assay for the early detection of lung cancer using sputum
Study: NCT01483157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vascular occlusion with exercise trainig
Description: twelve weeks of resistance training with vascular occlusion twice a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity resistance training
Description: twelve weeks of resistance training twice a week
Study: NCT02964715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25 mg daily for 6 months
Study: NCT03176043

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Fluid Administration
Description: Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV Fluid Administration
Description: Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
Study: NCT01947595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intensified lifestyle intervention
Description: * physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: normal lifestyle intervention
Description: * physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: normal lifestyle intervention
Description: * physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single lifestyle advice
Description: - Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25\> kg/m²)
Study: NCT03857841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNEX-42
Description: UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNEX-42
Description: UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNEX-42
Description: UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Phosphate-buffered saline
Study: NCT04496843

Intervention type: DIAGNOSTIC_TEST
Intervention: HWA09 Measurement
Description: Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
Study: NCT04216979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy entry policy
Description: Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy entry policy
Description: Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy entry policy
Description: Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site.
Study: NCT03792321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000 mg i.m. every 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000 mg i.m. every 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00567489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutrineal
Description: Amino Acids 1.1%
Study: NCT00474929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
Study: NCT00710112

Intervention type: GENETIC
Intervention: gene variations
Description: comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
Study: NCT01996072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study: NCT00010439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
Study: NCT00518128

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical OSA treatment
Description: uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure Therapy
Description: Continuous positive airway pressure for treatment of obstructive sleep apnea
Study: NCT00947037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-CD/LD
Study: NCT00871403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib and pemetrexed
Description: oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed and cisplatin
Description: pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
Study: NCT01995019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: 1 ml single dose Intra-articular Depo-Medrol 40 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline
Description: 1 ml intra-articular placebo
Study: NCT03389841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education of the caregiver about early symptoms and signs of heart failure
Study: NCT02840175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study: NCT00884858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
Study: NCT03431090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® TCRαβ/CD19 Combined Depletion System
Description: The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
Study: NCT01982214

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sedentary
Description: No intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
Study: NCT01987596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
Study: NCT02840175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study: NCT02127827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Ambulatory Glycemic Controller (AAGC)
Study: NCT03644355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Inter-disciplinary, interactive, family based behavioral intervention for overweight children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Inter-disciplinary, interactive, family based behavioral intervention for overweight children

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Inter-disciplinary, interactive, family based behavioral intervention for overweight children
Study: NCT02309177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study: NCT03460496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neonatologists
Description: will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support
Description: Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lactation consultant
Description: during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapeutic interventions
Description: physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social workers
Description: social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
Study: NCT02338297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transarterial chemoembolisation (TACE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolisation (TACE)
Study: NCT03460496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: other health care professionals
Description: the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
Study: NCT02338297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGM
Description: Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVA
Description: Occlude arterioportal shunts(APS) with PVA
Study: NCT01729000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gloves
Description: All staff must wear gloves for subjects that are in the experimental group.
Study: NCT03460496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interprofessional roundtable meetings
Description: interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
Study: NCT02971475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave lithotripsy
Description: People in this group would be treated with ESWL only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic drainage of the main pancreatic duct
Description: People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.